Please check your internet connection and try again.
### Overview
Miconazole is an imidazole antifungal agent. The query specifies "miconazole vaginal pessary," which is an unusual formulation. Miconazole is commonly available as vaginal suppositories or creams for the treatment of vulvovaginal candidiasis. Pessaries are typically used for pelvic organ prolapse or urinary incontinence, and are not usually impregnated with antifungal medication. It is possible the request refers to a miconazole vaginal suppository or cream intended for vaginal insertion, and the term "pessary" is used incorrectly.
### Primary Indications
* Treatment of vulvovaginal candidiasis (yeast infections).
### Adult Dosing
Dosing is typically based on the available formulation (suppository or cream).
* **Suppositories:**
* 100 mg inserted vaginally once daily at bedtime for 7 days.
* 200 mg inserted vaginally once daily at bedtime for 3 days.
* One (1200 mg) single-dose vaginal suppository inserted at bedtime.
* **Vaginal Cream:**
* 2% cream: One applicatorful (approximately 5 grams) inserted vaginally at bedtime for 7 days.
* 4% cream: One applicatorful (approximately 5 grams) inserted vaginally at bedtime for 3 days.
* 2% cream (single dose): One applicatorful (approximately 5 grams) inserted vaginally.
### Pediatric Dosing
Dosing for pediatric patients (under 12 years) is not well established for vaginal miconazole. Consultation with a healthcare provider is recommended.
### Dose Adjustments
No dose adjustments are typically required for renal or hepatic impairment for vaginal formulations.
### Contraindications
* Known hypersensitivity to miconazole or any component of the formulation.
### Adverse Effects
* **Common:** Vaginal burning, itching, irritation, pelvic cramps.
* **Less Common:** Headache, rash.
### Key Drug Interactions
* **Warfarin:** Miconazole can inhibit CYP2C9, potentially increasing the anticoagulant effect of warfarin. Monitor INR closely if coadministered. This interaction is less likely to be clinically significant with vaginal formulations due to limited systemic absorption, but caution is still advised.
### Monitoring
* Monitor for signs and symptoms of vaginal candidiasis.
* Monitor for adverse effects.
* If coadministered with warfarin, monitor INR.
### Clinical Pearls
* Complete the full course of treatment, even if symptoms improve.
* Avoid sexual intercourse during treatment to prevent reinfection or transmission.
* Partners may require treatment if they have symptoms.
* If symptoms do not improve after completing treatment, consult a healthcare provider for re-evaluation, as alternative diagnoses or resistant organisms may be present.
* If the patient is using a pessary for pelvic organ support, and the intent was to coat it with miconazole cream, this is not a standard or recommended practice. Consult with a healthcare provider regarding appropriate management of pelvic organ prolapse and any concurrent vaginal infections.
***
*This information is intended for clinical decision-making and is not a substitute for professional medical advice. Always consult the current prescribing information and a healthcare provider for any patient-specific questions.*
